In the Specification

Please substitute the Title of the invention on page 1, line 1:

~~HUMAN CDNAS AND PROTEINS~~ PLASMIN VARIANTS AND USES THEREOF

Please substitute the following paragraph on page 200, beginning at line 24:

Plasminute is the product of alternative transcription initiation within the plasminogen gene. Transcription initiates within intron N (at least 1036 nucleotides upstream of exon XV) and proceeds through the remainder of the plasminogen gene (Petersen, TE et al., J. Biol. Chem. 265:6104-11 (1990); NCBI Accession No. AL109933.25 which disclosures are hereby incorporated by reference in their entirety). Splicing occurs normally between transcribed exons XV to XIX. Translation initiates within exon XV and is carried out in the plasminogen open reading frame. Plasminute represents the carboxyl-terminal fragment of plasminogen corresponding to amino acids 585 to ~~790~~ 791 (numbered from the amino-terminal glutamic acid residue of secreted plasminogen).

Please substitute the following "Abstract" paragraph on page 394, beginning at line 2:

The invention concerns plasmin variants. Polynucleotides the disclosed plasmin variants are provided. Additionally, methods of using the plasmin polynucleotides and polypeptides are provided herein ~~GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, and~~ in the ~~production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.~~